Full-Time
Lead – Strategic Workforce Planning & Analytics
Posted on 6/27/2026
Agilent Technologies
10,001+ employees
Provides eProcurement automation and hosted catalogs
Compensation Overview
$210.5k - $328.9k/yr
Company Does Not Provide H1B Sponsorship
Santa Clara, CA, USA
Hybrid
Three days on-site per week required.
 People & HR (1) |
|---|
Get referred to Agilent Technologies
Find people who can refer or advise you
- 12+ years of experience in workforce planning, workforce analytics, people analytics, FP&A, consulting, or a related field, with enterprise or global scope.
- Bachelor’s degree required; advanced degree in Business, Finance, HR, Analytics, or a related field preferred.
- Proven experience building or leading strategic workforce planning capabilities in complex, matrixed organizations.
- Deep expertise in headcount planning, workforce modeling, labor cost forecasting, and scenario analysis.
- Strong ability to connect workforce strategy to financial planning, business strategy, and operating model decisions.
- Experience partnering closely with Finance on workforce planning tied to operating plans, forecasts, and long-range planning.
- Experience translating workforce demand into hiring strategy in partnership with Recruiting or Talent Acquisition.
- Advanced analytical and data storytelling skills, with experience using tools such as Workday Adaptive Planning, Power BI, Tableau, Anaplan, or similar.
- Strong understanding of HR and workforce data ecosystems (HRIS, ATS, Finance), with preference for Workday environments.
- Practical fluency in AI and automation, with the ability to assess implications for workforce composition, productivity, and cost.
- Proven ability to influence senior stakeholders across HR, Finance, and the business in complex, cross-functional environments.
- Build and lead Agilent’s enterprise strategic workforce planning capability, including frameworks, governance, planning cadence, and executive reporting.
- Own the integrated workforce plan, connecting headcount, skills, workforce mix, labor cost, capacity, and business priorities into a single, actionable view.
- Serve as a strategic advisor to HR, Finance, and business leaders on workforce strategy, investment decisions, and long-range planning scenarios.
- Partner with Finance to align workforce planning with annual operating plans, forecasts, long-range planning, and enterprise scenario modeling.
- Translate workforce demand into hiring strategies by partnering with Recruiting on capacity models, pipeline strategy, and time-to-fill assumptions.
- Build predictive and scenario-based models for attrition, mobility, skills gaps, hiring demand, productivity, and workforce readiness.
- Integrate workforce data across HR, Finance, and business systems to establish a reliable source of truth for planning and decision-making.
- Lead cross-functional planning across HRBPs, Finance, Recruiting, People Operations, and Facilities to align workforce, cost, and capacity decisions.
- Translate AI, automation, and digital labor trends into workforce strategies, including impacts to productivity, workforce mix, and future capability needs.
- Deliver executive dashboards and insights that drive decisions on workforce investments, transformation priorities, and operational performance.
- Experience in life sciences, healthcare, diagnostics, technology, or other complex, regulated industries.
- Experience building a workforce planning function or Center of Excellence from the ground up.
- Consulting background or experience with enterprise transformation initiatives.
- Experience incorporating contingent labor, outsourced services, and digital/AI-driven capacity into workforce models.
Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.
Company Size
10,001+
Company Stage
IPO
Headquarters
Santa Clara, California
Founded
1999
Get referred to Agilent Technologies
Find people who can refer or advise you
Simplify's Take
What believers are saying
- A 200–300 basis point tailwind from aging lab equipment replacement cycles drives demand.
- GLP-1 weight-loss drug development creates structural revenue growth for Agilent's quality assurance instruments.
- AI-enabled oncology testing via the Biocare acquisition expands cancer diagnostics capabilities in 2026.
- The multi-attribute method workflow enables LC/HRMS in routine testing, consolidating traditional multi-test measurements.
- Management targets 4–6% organic growth in fiscal 2026, supported by life sciences secular tailwinds.
- Equity analysts estimate 27% upside to $161 driven by margin improvements and consumables revenue growth.
What critics are saying
- Thermo Fisher's $40B scale compresses Agilent’s pricing power in LC/GC markets with 45–60% probability in 6–12 months.
- China funding delays suppress Asia Pacific demand by 6.7%, reducing $553M quarterly intake within 3–9 months.
- Biotech funding collapse cuts LC/MS consumables demand by 15–20%, eroding Agilent’s >50% recurring revenue base.
- AI-simulated research threatens 10–15% physical lab instrument order reduction in pharma R&D over 12–18 months.
- QIAGEN acquisition speculation triggers $200–300M capex diversion and regulatory scrutiny, delaying AI diagnostics push.
- $3.55B total debt forces $450M annual investment cut, crippling CrossLab’s 32% recurring revenue growth within 6–12 months.
What makes Agilent Technologies unique
- Agilent leads the GC market and ranks top-three in LC/MS with vendor-neutral consumables.
- The company runs a razor-and-blade model generating over 50% recurring revenue from consumables and services.
- Agilent leverages biopharma and clinical diagnostics growth via the IGNITE operating system and targeted M&A.
- Its Altura SEC columns deliver double sensitivity for GLP-1 peptide analysis in biopharmaceutical workflows.
- The PD-L1 test now covers four new cancer types, consolidating PD-L1 testing across tumor types.
- Agilent's OpenLab Sync digitally connects scientific workflows, improving data integrity in regulated laboratory environments.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Performance Bonus
Stock Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.
Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.
Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.
Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t
Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction